In addition, CLL-IPI risk scores were differently distributed in the lnc-KIAA1755-4low and lnc-KIAA1755-4high groups; patients with low CLL-IPI were predominant in the lnc-KIAA1755-4low group, while patients with intermediate, high and very high CLL-IPI were predominant in the lnc-KIAA1755-4high group (p = 0.015, Fisher exact test). Here, KIAA1755 is linked to B-cell chronic lymphocytic leukemia.